eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2018
vol. 69
 
Share:
Share:
more
 
 
abstract:
Review paper

A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects

Naoto Kuroda, Emiko Sugawara, Hironori Kusano, Yoshiaki Yuba, Kenji Yorita, Kengo Takeuchi

Pol J Pathol 2018; 69 (2): 109-113
Online publish date: 2018/07/06
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
ALK-rearranged renal cell carcinoma (ALK-RCC) has been recently proposed and incorporated into the recent World Health Organisation Classification of renal tumours as a provisional entity. In this article, we review ALK-RCC with a focus on clinical and pathobiological aspects. Seventeen cases have been described to date. ALK-RCC accounts for less than 1% of all renal tumours. The age of patients ranges from 6 to 61 years with a mean age of 29.6 years. Grossly, the tumour forms were ill-demarcated or well demarcated solid mass in the renal medulla. Histologically, RCC with VCL-ALK translocation resembles renal medullary carcinoma and mucinous cribriform pattern, signet-ring cell pattern and solid rhabdoid pattern are often observed in RCC with non-VCL-ALK fusion. Immunohistochemically, ALK protein diffusely expresses and TFE3 is often expressed. ALK gene can fuse to VCL, TPM3, EML4, HOOK1 or STRN gene. A break-apart fluorescence in situ hybridisation study is clinically available for the practice of definite diagnosis. ALK inhibitor therapy will provide great benefit for patients with advanced stage of ALK-RCC in the near future.
keywords:

ALK, renal cell carcinoma, pathology, review

references:
Yoshida MA, Ohyashiki K, Ochi H, et al. Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res 1986; 46: 2139-2147.
Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994; 263: 1281-1284.
Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997; 89: 1483-1490.
Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000; 157: 377-384.
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
Pérot G, Soubeyran I, Ribeiro A, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One 2014; 9: e87170.
Chou A, Fraser S, Toon CW, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 2015; 39: 652-659.
Taguchi R, Higuchi K, Sudo M, et al. A case of anaplastic lymphoma kinase (ALK)-positive ciliated muconodular papillary tumor (CMPT) of the lung. Pathol Int 2017; 67: 99-104.
Jin Y, Shen X, Shen L, et al. Ciliated muconodular papillary tumor of the lung harboring ALK gene rearrangement: Case report and review of the literature. Pathol Int 2017; 67: 171-175.
Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011; 24: 430-442.
Merino-Enriquez A, Ou WB, Weldon CB, et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 2011; 50: 146-153.
Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012; 118: 4427-4436.
Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol 2012; 25: 1516-1525.
Hodge JC, Pearce KE, Sukov WR. Distinct ALK-rearranged and VCL-negative papillary renal cell carcinoma variant in two adults without sickle cell trait. Mod Pathol 2013; 26: 604-616.
Lee C, Park JW, Suh JH, et al. ALK-positive renal cell carcinoma in a large series of consecutively resected Korean renal cell carcinoma patients. Korean J Pathol 2013; 47: 452-457.
Smith NE, Deyrup AT, Marino-Enriquez A, et al. VCL-ALK renal cell carcinoma in children with sickle-cell trait. The eighth sickle-cell nephropathy? Am J Surg Pathol 2014; 38: 858-863.
Cajaiba MM, Jennings LJ, Rohan SM, et al. ALK-arranged renal cell carcinomas in children. Genes Chromosomes Cancer 2016; 55: 442-451.
Cajaiba MM, Jennings LJ, George D, et al. Expanding spectrum of ALK-rearranged renal cell carcinomas in children: identification of a novel HOOK1-ALK fusion transcript. Genes Chromomes Cancer 2016; 55: 814-817.
Jeanneau M, Gregoire V, Desplechain C, et al. ALK-rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. Pathol Res Pract 2016; 212: 1064-1066.
Thorner PS, Shago M, Marrano P, et al. TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with TPM3-ALK translocation. Pathol Res Pract 2016; 212: 937-942.
Kusano H, Togashi Y, Akiba J, et al. Two cases of renal cell carcinoma harboring a novel STRN-ALK fusion gene. Am J Surg Pathol 2016; 40: 761-769.
Chen YB, Xu J, Skanderup AJ, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun 2016; 7: 13131.
Srigley JR, Delahunt B, Eble JN, et al.; ISUP renal tumor panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 2013; 37: 1469-1489.
Moch H, Humphrey PA, Ulbright TM, et al. In: World Health Organization Classification of Tumours of Urinary System and Male Genital Organs. IARC Press, Lyon 2016.
Udagar AM, Mehra R. Morphologic, molecular, and taxonomic evolution of renal cell carcinoma. Arch Pathol Lab Med 2016; 140: 1026-1037.
Rao Q, Xia QY, Cheng L, et al. Molecular genitcs and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res 2016; 28: 29-49.
Kuroda N, Tanaka A, Ohe C, et al. Recent advances of immunohistochemistry of diagnosis renal tumors. Pathol Int 2013; 63: 381-390.
Kuroda N, Hes O, Zhou M. New and emerging renal tumour entities. Diagn Histopathol 2016; 22: 47-56.
Liu Q, Galli S, Srinivasan R, et al. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol 2013; 37: 368-374.
Kuroda N, Toi M, Hiroi M, et al. Review of collecting duct carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2002; 17: 1329-1334.
Kuroda N, Toi M, Hiroi M, et al. Review of mucinous tubular and spindle cell carcinoma of the kidney with a focus on clinical and pathobiological aspects. Histol Histopathol 2005; 20: 221-224.
Kuroda N, Toi M, Hiroi M, et al. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003; 18: 487-494.
Kuroda N, Mikami S, Pan C, et al. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspects. Histol Histopathol 2012; 27: 133-140.
Kuroda N, Yorita K, Sasaki N, et al. Clinicopathological study of 5 cases of renal cell carcinoma with t(6;11)(p21;q12). Pol J Pathol 2017; 68: 66-72.
Kuroda N, Yorita K, Nagasaki M, et al. Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects. Pol J Pathol 2016; 67: 3-7.
Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011; 35: 1226-1234.
Buraczewska A, Kardas J. Axitinib in metastatic renal cell carcinoma: single center experience. Contemp Oncol (Pozn) 2016; 20: 481-485.
Ryan C, Mayer N, Cunningham J, et al. Increased ALK1 copy number and renal cell carcinoma-a case report. Virchows Arch 2014; 464: 241-245.
Ferician O, Cimpean AM, Ceausu AR, et al. Heterogenous vascular pattern in renal cell carcinomas. Pol J Pathol 2016; 67: 46-53.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe